AbbVie’s stock ticked up 1.17% to $266.27 following the European Commission’s nod for RINVOQ to treat severe alopecia areata in patients aged 12 and older. This approval opens a new market segment for the drug, which was previously authorized for multiple autoimmune diseases across Europe.
RINVOQ’s Expanded Role in Autoimmune Treatment
The approved doses, 15 and 30 milligrams taken once daily, come from data collected in two placebo-controlled Phase 3 clinical trials. These studies focused on patients with severe hair loss caused by alopecia areata. After 24 weeks, a significantly higher number of those taking RINVOQ achieved at least 80% scalp hair coverage compared to the placebo group, with some experiencing full regrowth.
Beyond scalp hair, improvements were also seen in eyebrows and eyelashes. The safety profile remained consistent with prior findings in conditions like rheumatoid arthritis and Crohn’s disease, where RINVOQ is already approved.
Strategic Growth Amid Competitive Pressures
This approval helps AbbVie broaden RINVOQ’s footprint in dermatology, alongside existing indications for inflammatory diseases. The company is pushing into new specialties as it faces competition challenging older drugs in its portfolio. Expanding into alopecia areata gives AbbVie a more diversified revenue base in the European market.
The growing acceptance of RINVOQ highlights AbbVie’s commitment to targeting immune pathways that underlie multiple tough-to-treat conditions. By offering an oral treatment option that delivers measurable results in hair regrowth, AbbVie gains a competitive edge in autoimmune therapies.
This article is for informational purposes and does not constitute financial advice.
